Richard Kim1, Gopi Kesaria Prithviraj2, Ravi Shridhar3, Sarah E Hoffe3, Kun Jiang4, Xiuhua Zhao5, Dung-Tsa Chen5, Khaldoun Almhanna2, Jonathan Strosberg2, Tiffany Campos2, David Shibata2. 1. Departments of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA. Electronic address: Richard.Kim@moffitt.org. 2. Departments of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA. 3. Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA. 4. Department of Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA. 5. Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA.
Abstract
PURPOSE: The standard of care in locally advanced rectal cancer is preoperative treatment with fluoropyrimidine-based chemoradiotherapy. Sorafenib works synergistically with radiation and inhibits Ras/Raf, PDFGR, and VEGFR. This phase I study evaluated the safety and efficacy of sorafenib with infusional 5-fluorouracil (5-FU) and radiation in patients with locally advanced rectal cancer. METHODS AND MATERIALS: Patients with confirmed stage II or III rectal cancer were recruited in 4 cohorts of 3 patients per dose level, with an expansion cohort at the maximum tolerated dose. A 3+3 dose escalation design was used. Radiation was given in 28 fractions at 1.8 Gy (50.4 Gy) day 1-5 at all dose levels. Initial dose of sorafenib was 200mg qd and titrated up to 400mg BID to determine the MTD. Standard dose of infusional 5-FU was used (225 mg/m(2)/24h). Patients underwent surgery 6-10 weeks after neoadjuvant therapy. RESULTS: Between August 2011 and August 2014, 17 patients (median age of 54 years) were enrolled. After toxicities requiring dose interruptions were observed in cohort 1 (2 patients with grade 2 (G2) and grade 3 (G3) hand foot skin reaction and 1 patient with G2 mucositis), the protocol was amended, changing administration of chemotherapy and sorafenib from daily to days 1-5 only. With the amended protocol, the primary G3 toxicity was hypertension in 2 patients at the 200-mg adjusted dose level (day1-5) and 1 patient at the 400-mg twice daily dose level. One patient had G3 ALT elevation at 400mg, and no grade IV toxicities were observed. G1 and G2 toxicities included hand-foot skin reaction, diarrhea, mucositis, nausea, fatigue, and proctitis. No perioperative complications were seen. Two patients refused to undergo surgery. The pathological complete remission (pCR) rate was 33%, and downstaging was observed in 85.7% of patients. Median neoadjuvant rectal cancer score was 8.7. CONCLUSIONS: With the changed dosing schedule, this regimen was very well tolerated. The tumor pCR and downstaging rates are encouraging and support further clinical investigation of this regimen.
PURPOSE: The standard of care in locally advanced rectal cancer is preoperative treatment with fluoropyrimidine-based chemoradiotherapy. Sorafenib works synergistically with radiation and inhibits Ras/Raf, PDFGR, and VEGFR. This phase I study evaluated the safety and efficacy of sorafenib with infusional 5-fluorouracil (5-FU) and radiation in patients with locally advanced rectal cancer. METHODS AND MATERIALS: Patients with confirmed stage II or III rectal cancer were recruited in 4 cohorts of 3 patients per dose level, with an expansion cohort at the maximum tolerated dose. A 3+3 dose escalation design was used. Radiation was given in 28 fractions at 1.8 Gy (50.4 Gy) day 1-5 at all dose levels. Initial dose of sorafenib was 200mg qd and titrated up to 400mg BID to determine the MTD. Standard dose of infusional 5-FU was used (225 mg/m(2)/24h). Patients underwent surgery 6-10 weeks after neoadjuvant therapy. RESULTS: Between August 2011 and August 2014, 17 patients (median age of 54 years) were enrolled. After toxicities requiring dose interruptions were observed in cohort 1 (2 patients with grade 2 (G2) and grade 3 (G3) hand foot skin reaction and 1 patient with G2 mucositis), the protocol was amended, changing administration of chemotherapy and sorafenib from daily to days 1-5 only. With the amended protocol, the primary G3 toxicity was hypertension in 2 patients at the 200-mg adjusted dose level (day1-5) and 1 patient at the 400-mg twice daily dose level. One patient had G3 ALT elevation at 400mg, and no grade IV toxicities were observed. G1 and G2 toxicities included hand-foot skin reaction, diarrhea, mucositis, nausea, fatigue, and proctitis. No perioperative complications were seen. Two patients refused to undergo surgery. The pathological complete remission (pCR) rate was 33%, and downstaging was observed in 85.7% of patients. Median neoadjuvant rectal cancer score was 8.7. CONCLUSIONS: With the changed dosing schedule, this regimen was very well tolerated. The tumor pCR and downstaging rates are encouraging and support further clinical investigation of this regimen.
Authors: Li Liu; Yichen Cao; Charles Chen; Xiaomei Zhang; Angela McNabola; Dean Wilkie; Scott Wilhelm; Mark Lynch; Christopher Carter Journal: Cancer Res Date: 2006-12-15 Impact factor: 12.701
Authors: Vincenzo Valentini; Ruud G P M van Stiphout; Guido Lammering; Maria Antonietta Gambacorta; Maria Cristina Barba; Marek Bebenek; Franck Bonnetain; Jean-Francois Bosset; Krzysztof Bujko; Luca Cionini; Jean-Pierre Gerard; Claus Rödel; Aldo Sainato; Rolf Sauer; Bruce D Minsky; Laurence Collette; Philippe Lambin Journal: J Clin Oncol Date: 2011-07-11 Impact factor: 44.544
Authors: Ralf-Dieter Hofheinz; Frederik Wenz; Stefan Post; Axel Matzdorff; Stephan Laechelt; Jörg T Hartmann; Lothar Müller; Hartmut Link; Markus Moehler; Erika Kettner; Elisabeth Fritz; Udo Hieber; Hans Walter Lindemann; Martina Grunewald; Stephan Kremers; Christian Constantin; Matthias Hipp; Gernot Hartung; Deniz Gencer; Peter Kienle; Iris Burkholder; Andreas Hochhaus Journal: Lancet Oncol Date: 2012-04-13 Impact factor: 41.316
Authors: Michael J O'Connell; Linda H Colangelo; Robert W Beart; Nicholas J Petrelli; Carmen J Allegra; Saima Sharif; Henry C Pitot; Anthony F Shields; Jerome C Landry; David P Ryan; David S Parda; Mohammed Mohiuddin; Amit Arora; Lisa S Evans; Nathan Bahary; Gamini S Soori; Janice Eakle; John M Robertson; Dennis F Moore; Michael R Mullane; Benjamin T Marchello; Patrick J Ward; Timothy F Wozniak; Mark S Roh; Greg Yothers; Norman Wolmark Journal: J Clin Oncol Date: 2014-05-05 Impact factor: 44.544
Authors: M Mohiuddin; M Hayne; W F Regine; N Hanna; P F Hagihara; P McGrath; G M Marks Journal: Int J Radiat Oncol Biol Phys Date: 2000-11-01 Impact factor: 7.038
Authors: Carmen Timke; Heike Zieher; Alexandra Roth; Kai Hauser; Kenneth E Lipson; Klaus J Weber; Jürgen Debus; Amir Abdollahi; Peter E Huber Journal: Clin Cancer Res Date: 2008-04-01 Impact factor: 12.531
Authors: Christopher G Willett; Yves Boucher; Emmanuelle di Tomaso; Dan G Duda; Lance L Munn; Ricky T Tong; Daniel C Chung; Dushyant V Sahani; Sanjeeva P Kalva; Sergey V Kozin; Mari Mino; Kenneth S Cohen; David T Scadden; Alan C Hartford; Alan J Fischman; Jeffrey W Clark; David P Ryan; Andrew X Zhu; Lawrence S Blaszkowsky; Helen X Chen; Paul C Shellito; Gregory Y Lauwers; Rakesh K Jain Journal: Nat Med Date: 2004-01-25 Impact factor: 53.440
Authors: Jorge Aparicio; Carmen García-Mora; Marta Martín; Ma Lourdes Petriz; Jaime Feliu; Ma Elena Sánchez-Santos; Juan Ramón Ayuso; David Fuster; Carlos Conill; Joan Maurel Journal: PLoS One Date: 2014-01-09 Impact factor: 3.240
Authors: Rutika Mehta; Jessica Frakes; Jongphil Kim; Andrew Nixon; Yingmiao Liu; Lauren Howard; Maria E Martinez Jimenez; Estrella Carballido; Iman Imanirad; Julian Sanchez; Sophie Dessureault; Hao Xie; Seth Felder; Ibrahim Sahin; Sarah Hoffe; Mokenge Malafa; Richard Kim Journal: Oncologist Date: 2022-08-05 Impact factor: 5.837